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Abstract Chemical pleurodesis is widely used in symp-
tomatic patients with malignant pleural effusion to 
relieve symptoms, prevent fl uid recurrence, and improve 
quality of life. Talc has been repeatedly found to be the 
most effective sclerosant agent, and thoracoscopic talc 
poudrage has been found to be the most effective 
pleurodesis technique. A homogeneous talc distribution 
on the visceral and parietal pleura helps to achieve com-
plete pleural symphysis. We have recently adopted a new 
suitable sterile device that delivers talc under low and 
constant pressure, facilitating uniform coating of the 
whole pleural surface and avoiding inappropriate depo-
sition of talc clumps.
Key words Pleural effusion · Pleural space · Thoracos-
copy/video-assisted thoracoscopic surgery (VATS)
Introduction
Malignant pleural effusion (MPE) is a common and 
serious clinical problem with an estimated incidence as 
high as 100 per 100,000 population.1 The majority of 
patients develop recurrent pleural accumulation with 
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resultant dyspnea, chest pain, cough, or a combination 
of these symptoms that negatively affect quality of life.
Chemical pleurodesis is widely used as a palliative 
treatment option in symptomatic patients with MPE. 
Two recent systematic reviews2,3 found that the relative 
risk for successful pleurodesis favored talc over other 
sclerosants and suggested that thoracoscopic talc pou-
drage was the technique of choice for pleurodesis in 
patients with MPE.
Intuitively, a homogeneous talc distribution on the 
visceral and parietal pleura helps to successfully obliter-
ate the pleural space.
We have recently adopted a new suitable sterile device 
that delivers talc under low and constant pressure, facili-
tating uniform coating of the whole pleural surface while 
avoiding inappropriate deposition of talc clumps.
Case reports
Between August 1, 2009, and October 13, 2009, ten 
consecutive patients with recurrent malignant pleural 
effusion (ovarian carcinoma, 1; vulva squamous cell 
carcinoma, 1; breast cancer, 1; sarcomatoid carcinoma, 
1; non-small cell lung cancer, 1; malignant pleural meso-
thelioma, 5) were treated with thoracoscopic talc pou-
drage using the new device and were prospectively 
followed up until June 1, 2010. All patients gave informed 
written consent, and the study was approved by the local 
Institutional Review Board.
Thoracoscopic talc poudrage was performed with a 
uni-portal video-assisted thoracic surgical approach 
under local anesthesia and conscious sedation. A 10-mm 
operating thoracoscope was used. Pleural fl uid was 
aspirated, and biopsy specimens of the parietal pleura 
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Fig. 1 A 36-year-old woman with recurrent pleural effusion and 
previous history of metastatic ovarian carcinoma. Thoracoscopic 
view shows homogeneous distribution of talc on the pleural 
surfaces
Fig. 2 A A view of the system 
(1, the air fi lter; 2, the small 
clump). B (inset): Plastic 
canister with the pigtail tube 
and the small ball, necessary 
to obtain a whirling fl ow
(Fig. 1) were taken for diagnostic purposes. Under visu-
alization, talc was insuffl ated via a catheter through the 
working channel of the operating thoracoscope using the 
new device (Sprink Sestriere; Eurosets, Medolla, Italy) 
(Fig. 2). Four grams of sterilized graded talc was put into 
the device.
The device consists of a plastic canister containing a 
small ball and a pigtail tube (Fig. 2B) through which 
pressurized air (1.1–1.2 bar) is insuffl ated after being 
sterilized by a fi lter (Fig. 2A). The pigtail tube generates 
a circular current of high-pressure air, which, with the 
aid of the entrained ball, creates an homogeneous fi ne 
particulate talc mist. Furthermore, a clamp allows the 
operator to regulate the fl ow rate (Fig. 2A). At the end 
of the procedure, talc appears evenly distributed over the 
pleural surfaces (Fig. 1C).
Results
There were no procedure-related complications. The 
median duration of chest tube use was 3.5 days (range, 
2–11 days). The median duration of postoperative hos-
pitalization was 4 days (range, 2–13 days).
No recurrent pleural effusions were observed over a 
median follow-up of 9 months (range, 7.6–10.5 months).
We compared our results with an historical group of 
13 patients (3, malignant mesothelioma; 8, pulmonary 
adenocarcinoma; 1, B-cell lymphoma; 1, adrenal gland 
carcinoma) undergoing VATS talc pleurodesis with the 
system adopted in our department previously between 
June 1, 2009 and July 30, 2009 (a syringe with talc con-
nected to a pressurized air system). The median duration 
of chest tube use was 3.0 days (range, 2–19 days). The 
median duration of postoperative hospitalization was 6 
days (range, 3–8 days). Two recurrent pleural effusion 
were observed over a median follow-up of 7.4 months 
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(range, 5.8–8.3 months). There was an increase in the 
successful rate of 15%, but no statistical difference 
was seen between these two groups (Fisher’s exact test, 
P = 0.3)
Discussion
The majority of patients with malignant pleural effusion 
suffer from progressive dyspnea, chest pain, or cough. 
Chemical pleurodesis may be used in selected patients 
with acceptable performance status and life expectancy 
greater than 3 months to relieve symptoms, prevent fl uid 
recurrence, and improve the quality of life.1,4 Talc is 
widely recognized as the sclerosant agent of choice in 
view of its clinical effi cacy, safety profi le, and low cost, 
whereas thoracoscopic talc pleurodesis has been sug-
gested as the most effective pleurodesis technique.2,3,5 In 
fact, during video-assisted thoracoscopy, pleural fl uid 
can be removed completely, loculations and adhesions 
can be divided when present, and talc can be insuffl ated 
equally in the pleural space under visual control.
The presence of a “trapped” lung by tumor or fi brin 
will universally result in an unsuccessful pleurodesis.1,6 
However, in patients who do not have a “trapped” lung, 
the failure rate of talc pleurodesis, reported in the litera-
ture, is still about 10%. In our department, the successful 
rate, before introducing this new device, was around 
80–90%. It is likely that nonhomogeneous or incomplete 
distribution of talc on the pleural surfaces will contribute 
to this failure rate.
Over the years, a number of atomizers or ad hoc 
devices have been used to insuffl ate talc in the pleural 
space.5,7,8 The new device, described here, produces a 
circular current of a fi nely adjustable fl ow of pressurized 
air, giving rise to a mist of talc particles that facilitates 
uniform coating of the whole pleural surface and avoids 
inappropriate deposition of talc clumps on the pleural 
surface. To obtain a consistent mist of talc particles, not 
more than 4 g talc should be used. Supplemental talc can 
be insuffl ated by using the same apparatus without 
increasing the cost of the procedure. In the preliminary 
laboratory model, we noticed that using a small canister 
and a pigtail tube with the talc connected to a positive 
pressure system creates an homogeneous pressure in the 
canister, generating an homogeneous fl ow in the catheter 
used for the pleurodesis. This method avoids an instan-
taneous fl ow of talc going into the chest without pressure 
control.
This is only a preliminary report to explain the 
feasibility of this new device for the thoracoscopic 
pleurodesis, showing possible advantages: ease of use, 
homogeneous talc distribution, and lower cost, if more 
than 4 g talc is required. Further study is needed to defi -
nitely demonstrate that more uniform and complete talc 
delivery on the pleural surface results in improved effi -
cacy of thoracoscopic talc poudrage. In this preliminary 
report we obtained a successful rate of 100%, compared 
to the successful rate of 85% in the historical group. This 
improvement is probably related to the more effective 
pleurodesis obtained with the new system. There was no 
statistical difference between these groups; even if there 
is an increased successful rate, this is probably related to 
the small number of patients used for the analysis.
Finally, this new device can also be considered a valu-
able option for video-assisted talc pleurodesis in patients 
with spontaneous pneumothorax.
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